KIT and acute myeloid leukemia: In the AML cell line Kasumi-1 bearing an N822K mutation in KIT exon 17, M4205 inhibited KIT autophosphorylation with an IC50 of 4 nmol/L, whereas SoC drugs were significantly less potent (ripretinib 12-fold, sunitinib 110-fold, and imatinib 190-fold; Fig. 3C).